Triple-negative breast cancer (TNBC) has been defined as a subtype of breast cancer negatively expressing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (1), accounting for ~15–20% of newly diagnosed breast cancer (2). This evidence concerns the gene ERBB2 and breast cancer.